Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tyme Technologies (NQ: TYME )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Sep 16, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tyme Technologies

Syros and Tyme Technologies Announce Stockholder Approval of Merger
From Syros Pharmaceuticals, Inc.
Via Business Wire
TYME TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TYME Technologies, Inc. - TYME
From Kahn Swick & Foti, LLC
Via Business Wire
TYME TECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of TYME Technologies, Inc. - TYME
From Kahn Swick & Foti, LLC
Via Business Wire
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
From Syros Pharmaceuticals
Via Business Wire
TYME Technologies, Inc. Announces Changes to its Board of Directors
From Tyme Technologies, Inc.
Via Business Wire
TYME Technologies, Inc. Provides Business Update and Announces Third Fiscal Quarter 2022 Financial and Operating Results
From TYME Technologies, Inc.
Via Business Wire
TYME Technologies, Inc. to Host Conference Call and Webcast on Friday, February 11, at 8:30 AM ET
From TYME Technologies, Inc.
Via Business Wire
TYME Technologies, Inc. Provides Update on Precision Promise Trial in Metastatic Pancreatic Cancer
From TYME Technologies, Inc.
Via Business Wire
TYME Technologies, Inc. to Present at H.C. Wainwright Bioconnect Virtual Conference
From TYME Technologies, Inc.
Via Business Wire
TYME Technologies, Inc. Announces Additional Encouraging Preclinical Data on the Effect of TYME-19 in SARS CoV-2 Infections
From TYME Technologies, Inc.
Via Business Wire
TYME Technologies, Inc. Announces Oral SM-88 Poster Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
From TYME Technologies, Inc.
Via Business Wire
TYME Technologies, Inc. Provides Business Update and Announces Second Fiscal Quarter 2022 Financial and Operating Results
From Tyme Technologies, Inc.
Via Business Wire
TYME Technologies, Inc. to Present at Jefferies London Healthcare Conference
From TYME Technologies, Inc.
Via Business Wire
TYME Technologies, Inc. to Host Conference Call and Webcast on Monday, November 8th at 8:30 AM ET
From TYME Technologies, Inc.
Via Business Wire
TYME Announces First Patient Dosed in Phase II OASIS Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with Metastatic HR+/HER2- Breast Cancer After Treatment with a CDK4/6 Inhibitor
From Tyme Technologies, Inc.
Via Business Wire
TYME Technologies, Inc. to Present at Upcoming Virtual Healthcare Industry Conferences
From TYME Technologies, Inc.
Via Business Wire
TYME Technologies, Inc. Provides Business Update and Announces Fiscal First Quarter 2022 Financial and Operating Results
From Tyme Technologies, Inc.
Via Business Wire
TYME Technologies, Inc. to Host Conference Call and Webcast on Tuesday, August 10th at 8:30 AM ET
From TYME Technologies, Inc.
Via Business Wire
Tyme Granted U.S. Patent Claims Covering Use of Tyrosine-Based Drug Delivery Method to Treat Cancer
From Tyme Technologies, Inc.
Via Business Wire
Tyme Technologies, Inc. Completes Strategic Review, Announces OASIS Breast Trial With Georgetown University, and Reports Fiscal Year 2021 Financial Results
From Tyme Technologies, Inc.
Via Business Wire
TYME Technologies, Inc. to Host Conference Call and Live Video Webcast on Thursday, June 10th at 5:00 PM ET
From TYME Technologies, Inc.
Via Business Wire
TYME Appoints Frank L. Porfido as Chief Financial Officer
From TYME Technologies, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.